Altasciences
Montreal, QC H3P 3P1, Canada
NCT Number: NCT05272683
The main purpose of this study is to determine the effect of itraconazole on the amount of GLPG3667 that gets into the blood when the 2 drugs are administered together compared to when GLPG3667 is administered alone.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Montreal, QC H3P 3P1, Canada
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
This list only contains the key inclusion criteria.
Exclusion criteria
This list only contains the key exclusion criteria.
On day 1 and day 8, participants will receive a single dose
On days 5 to 11, participants will receive itraconazole once daily
Time frame: From Day 1 pre-dose until Day 12
To determine the effect of itraconazole on the pharmacokinetics (PK) of GLPG3667
Time frame: From Day 1 pre-dose until Day 12
To determine the effect of itraconazole on the PK of GLPG3667
Time frame: From Day 1 through study completion, an average of 2 months
To evaluate the safety and tolerability of GLPG3667 alone or when co-administered with itraconazole
Lakefront Biotherapeutics NV
Industry
An Open-label, Fixed-sequence, Drug-drug Interaction Study in Healthy Subjects to Evaluate the Effect of Itraconazole, a Strong CYP3A4 Inhibitor and Potent P-gp Inhibitor on the Pharmacokinetics of GLPG3667
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details